Biosense Webster, Inc. announced that it has acquired Coherex
Medical, Inc. a privately held medical device company based in Salt Lake
City, Utah focused on the development of the Coherex WaveCrest®
Left Atrial Appendage (LAA) Occlusion System. The device is designed to
permanently occlude the LAA in high-risk atrial fibrillation (Afib)
patients to help reduce the incidence of stroke caused by the migration
of blood clots formed in the LAA, which is recognized as the source of
blood clots in approximately 90 percent of patients who have Afib.
Afib is associated with a five-fold increased risk of stroke and
prevention in patients with Afib represents a large unmet clinical need.
This acquisition reinforces the company's commitment to providing
innovative, minimally invasive therapies for the treatment of Afib,
which affects over 3 million patients in the United States and 20
million worldwide.
The Coherex WaveCrest® LAA occlusion system received CE Mark
in September 2013. It is not available for investigational use or
commercial distribution in the U.S. at this time.
